Marcello DiStasio1, Yigu Chen1, Deepa Rangachari2, Daniel B Costa2, Yael K Heher1, Paul A VanderLaan3. 1. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. 2. Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. 3. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. Electronic address: pvanderl@bidmc.harvard.edu.
Abstract
INTRODUCTION: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ≤ 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house. METHODS AND MATERIALS: To provide insights regarding the pre-testing, post-testing, and testing intervals that constitute the overall TAT target, we performed a detailed workflow analysis. A total of 157 lung cancer specimens were sent out for molecular testing at a commercial vendor from a single academic medical center during the calendar year 2015. RESULTS: Overall, 128 specimens (81.5%) met the recommended 10-working day TAT, with a median total TAT of 9 weekdays (mean ± standard deviation, 9.17 ± 4.15 days). The pre-testing interval was ≤ 3 days for 146 specimens (93.0%), and the post-testing reporting interval was < 1 day for 116 cases (73.9%). The TAT variance was not related to intrinsic specimen characteristics. CONCLUSION: Overall, the findings indicated that the CAP/IASLC/AMP TAT guideline recommendations are feasible for most lung cancer specimens when a streamlined system is in place.
INTRODUCTION: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ≤ 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house. METHODS AND MATERIALS: To provide insights regarding the pre-testing, post-testing, and testing intervals that constitute the overall TAT target, we performed a detailed workflow analysis. A total of 157 lung cancer specimens were sent out for molecular testing at a commercial vendor from a single academic medical center during the calendar year 2015. RESULTS: Overall, 128 specimens (81.5%) met the recommended 10-working day TAT, with a median total TAT of 9 weekdays (mean ± standard deviation, 9.17 ± 4.15 days). The pre-testing interval was ≤ 3 days for 146 specimens (93.0%), and the post-testing reporting interval was < 1 day for 116 cases (73.9%). The TAT variance was not related to intrinsic specimen characteristics. CONCLUSION: Overall, the findings indicated that the CAP/IASLC/AMP TAT guideline recommendations are feasible for most lung cancer specimens when a streamlined system is in place.
Authors: Amir Momeni-Boroujeni; Paulo Salazar; Tao Zheng; Nana Mensah; Ivelise Rijo; Snjezana Dogan; JinYuan Yao; Christine Moung; Chad Vanderbilt; Jamal Benhamida; Jason Chang; William Travis; Natasha Rekhtman; Marc Ladanyi; Khedoudja Nafa; Maria E Arcila Journal: J Mol Diagn Date: 2020-12-18 Impact factor: 5.568
Authors: Chao Shi; Bing Wei; Xiaohui Liu; Lin Meng; Chengzhi Zhao; Yuxi Chang; Rui Sun; Zhongxian Zhang; Yang Yu; Jie Ma Journal: Ann Transl Med Date: 2022-01
Authors: Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan Journal: J Am Soc Cytopathol Date: 2018-02-16
Authors: Ibiayi Dagogo-Jack; Christopher G Azzolli; Florian Fintelmann; Mari Mino-Kenudson; Anna F Farago; Justin F Gainor; Ginger Jiang; Zofia Piotrowska; Rebecca S Heist; Inga T Lennes; Jennifer S Temel; Meghan J Mooradian; Jessica J Lin; Subba R Digumarthy; Julie M Batten; Hayley Robinson; Vania Nose; Miguel Rivera; Valentina Nardi; Dora Dias-Santagata; Long P Le; Lecia V Sequist; Martha Pitman; Jo-Anne O Shepard; Alice T Shaw; A John Iafrate; Jochen K Lennerz Journal: JCO Precis Oncol Date: 2018-07-24